A public research surface · updated continuously
The drug supply chain will be won by whoever owns the chokepoints.
GLP-1 fill-finish, elastomer stoppers, bioprocessing resins, API reshoring, sterile injectables. Pharma Bottlenecks maps the manufacturing chain behind every blockbuster — not the molecules, the plants — and the listed companies that own each choke. Own the strait, not the tanker.
45 names tracked · 10 chokepoints · free, no login
The chokepoints
I
Sterile fill-finish capacity
GLP-1 demand turned aseptic fill-finish lines into the scarcest asset in pharma; capacity books out years ahead.
TMO · LLY · NVO · LZAGY · FUJIY · SIMTRA
II
Stoppers, syringes & drug-contact components
Every injectable passes through elastomer stoppers and glass barrels from two or three qualified suppliers — West's near-monopoly is the textbook choke.
WST · STVN · ATR · DTG.SW · GRRMY · YPHDF · SHLMEDICAL
III
Pharmaceutical glass & vials
Borosilicate vial and cartridge capacity concentrates in three companies; every injectable ramp strains it.
STVN · SHTPY · GLW · GRRMF · NPEGF
IV
Bioprocessing consumables & resins
Biologics manufacturing runs on single-use bags, filters and protein-A resin from an oligopoly with razor-blade economics.
RGEN · DHR · SDMHF · MKKGY · TMO · SOAGY
V
API & small-molecule reshoring
Most US generic APIs route through China and India; BIOSECURE-era reshoring is funded, dated, and capacity-constrained.
LZAGY · TMO · HKMPY · RDY · AMRX · SGFEF · WUXAY · USANTIBIOTICS
VI
CDMO capacity & the China exodus
WuXi handles a huge share of Western pipelines; every BIOSECURE headline reprices the non-Chinese CDMO bench.
LZAGY · TMO · WUXAY · WXIBF · FUJIY · CRL · SAMSUNGBIOLOGICS
VII
Peptide & oligonucleotide manufacturing
GLP-1s are peptides and the new genetic medicines are oligos — both need specialized synthesis capacity that is genuinely scarce.
BCHMY · LZAGY · A · MRVI · CORDENPHARMA
VIII
Sterile injectables & shortage economics
Chronic shortages in generic sterile injectables are a structural underinvestment story with FDA shortage lists as the public catalyst tape.
BAX · ICUI · AMRX · AMPH · HKMPY · FSNUY · VTRS
IX
Analytical instruments & QC release
Every batch released passes through chromatography, mass spec and sterility testing from a small instrument oligopoly.
WAT · A · MTD · TMO · DHR · CRL · BMXMF
X
Private giants & exposure vehicles
Catalent-under-Novo, Samsung Biologics, PolyPeptide, SHL — the manufacturing cap tables without US tickers, and the listed paths in.
WST · DAIKYOSEIKO · STVN · LZAGY · PLYGF · SGFEF · DTG.SW · NVO
Latest brief · 2026-07-27
Defensive injectables and packaging caught a bid while tools and glass slipped; West Pharmaceutical faded 8% after its earnings-day pop, days before 100% pharma tariffs land.
Baxter led the vertical, up 3.4% to $22.40 — the sterile-injectables chokepoint, whose IV solutions and drug-delivery systems sit at the center of chronic US shortage economics, catching a defensive-healthcare bid on a risk-off day. There was no fresh news; Baxter reports Q2 on July 30, and Friday was rotation into a cheap, essential-products name. AptarGroup (up 2.6% on drug packaging and delivery) and ICU Medical (up 2.6% on infusion and sterile injectables) rose alongside it.
West Pharmaceutical was the laggard, down 7.7% to $328.20, in a beat-and-fade. West reported Q2 net sales of $872.3M (up 13.8%) and adjusted EPS of $2.37 (up 28.8%), beating by roughly $0.29, and raised full-year guidance to $8.85–9.05 adjusted EPS on $3.345–3.38B of revenue. The stock had surged to a high on the print, then gave it back Friday on profit-taking. West owns the drug-contact-components chokepoint — the elastomer stoppers and seals on nearly every injectable vial — so the sell was valuation and positioning, not demand.
The analytical-tools and glass tiers were the soft spot. Corning fell 6.0% to $146.65 — the pharma-glass name behind Valor vials — sliding into its July 28 print; Repligen dropped 4.1% to $131.96 on the bioprocessing-resin line and Maravai 4.1% to $6.76, both falling with the growth complex, while Waters eased 2.0% ahead of its first quarter as the combined Waters/BD entity. The large-cap drug names were a mild offset, with Novo Nordisk up 1.2% and Eli Lilly up 0.9%.
The calendar is heavy and it ends on policy. Danaher and Corning report July 28, Samsung Biologics July 29, and Mettler-Toledo and Baxter July 30 — but the hard catalyst is July 31, when Section 232 pharmaceutical tariffs (100% on patented pharma and APIs) take effect. That single date reprices every chokepoint this vertical maps — API reshoring, CDMO capacity, fill-finish and glass — by making imported drug supply structurally more expensive. The prints are noise around it; the tariff is the signal.